Physician perspectives on Lp(a) testing and management in patients with cardiovascular disease: interviews from seven countries across five world health organization regions from INTERASPIRE
- PMID: 40879473
- DOI: 10.1093/eurjpc/zwaf527
Physician perspectives on Lp(a) testing and management in patients with cardiovascular disease: interviews from seven countries across five world health organization regions from INTERASPIRE
Abstract
Aims: Lipoprotein(a) (Lp(a)) is a genetic causal risk factor for atherosclerotic cardiovascular disease (ASCVD), irrespective of ancestry. INTERASPIRE is an international cohort study of secondary prevention conducted in 14 countries from all 6 WHO regions.
Methods and results: In a sub-study of seven countries (China, Colombia, Kenya, Nigeria, Malaysia, Poland, UAE), physicians involved in INTERASPIRE were contacted to investigate ASCVD knowledge and elicit perspectives on Lp(a) testing and management. Study physicians underwent telephone interviews conducted by trained research assistants in national languages using specially developed questionnaires. 245 physicians underwent interview: 55% cardiologists, 28% general physicians, 10% endocrinologists and 7% lipid specialists. 43% had access to Lp(a) measurement but, of these, only 50% measured it routinely, with significant variation between countries. Physicians were most likely to request Lp(a) testing in premature coronary disease (91%), after second or recurrent coronary event (81%) and in those with first-degree relatives with high Lp(a) (82%). More than two-thirds of physicians received Lp(a) results expressed in mass units. An elevated Lp(a) was defined variably, most commonly >50 mg/dL by 25%, and 32% were unsure or did not know. 94% believed that Lp(a) testing was beneficial and 81% would advise testing of first-degree relatives.
Conclusion: Whilst most physicians believe that Lp(a) testing would benefit patients and their relatives, there is marked heterogeneity in access to Lp(a) testing. Interpretation of an elevated Lp(a) varies widely and about one-third of physicians were unsure or did not know. There is a critical need for physician education on Lp(a) to inform decision-making in clinical practice.
Keywords: Cardiovascular risk; Lipoprotein(a); Physician perceptions; Secondary prevention of CVD.
Plain language summary
Lipoprotein(a), or Lp(a), is an inherited risk factor for heart disease, but how doctors test for and understand it varies around the world. In this study across seven countries, many doctors said they believe testing for Lp(a) is useful—especially in patients with early or repeated heart problems or a family history of high Lp(a)—but only about half of those with access to testing use it regularly. The study highlights a clear need for better education and clearer guidelines for doctors on how to use and interpret Lp(a) results to improve patient care.
© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest: none declared.
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
